1. Design and Selection of Toca 511 for Clinical Use: Modified Retroviral Replicating Vector With Improved Stability and Gene Expression
- Author
-
Taylor Buckley, Kei Hiraoka, Ryan Burnett, Akihito Inagaki, Christopher R. Logg, Cindy Burrascano, Douglas J. Jolly, Carlos E. Ibanez, Daniel L. Lohse, Karin Kristina Amundson, Dawn Jolson, Oscar Diago, Noriyuki Kasahara, Amy Lin, Omar D. Perez, and Harry E. Gruber
- Subjects
RNA Stability ,Flucytosine ,Gene Expression ,Cytosine Deaminase ,Mice ,0302 clinical medicine ,Interferon ,Gene expression ,Drug Discovery ,Murine leukemia virus ,Prodrugs ,Transgenes ,Vector (molecular biology) ,Genetics ,0303 health sciences ,biology ,Cytosine deaminase ,Molecular therapy ,3. Good health ,Leukemia Virus, Murine ,030220 oncology & carcinogenesis ,Molecular Medicine ,Original Article ,Fluorouracil ,Corrigendum ,medicine.drug ,Vocimagene Amiretrorepvec ,Transgene ,Genetic Vectors ,Stability (learning theory) ,Antineoplastic Agents ,Virus ,Fungal Proteins ,03 medical and health sciences ,Cell Line, Tumor ,medicine ,Animals ,Humans ,Molecular Biology ,Selection (genetic algorithm) ,030304 developmental biology ,Pharmacology ,Genetic Therapy ,Neoplasms, Experimental ,biology.organism_classification ,Virology ,Rats ,Oncolytic virus ,Neoplasm Transplantation - Abstract
Retroviral replicating vectors (RRVs) are a nonlytic alternative to oncolytic replicating viruses as anticancer agents, being selective both for dividing cells and for cells that have defects in innate immunity and interferon responsiveness. Tumor cells fit both these descriptions. Previous publications have described a prototype based on an amphotropic murine leukemia virus (MLV), encoding yeast cytosine deaminase (CD) that converts the prodrug 5-fluorocytosine (5-FC) to the potent anticancer drug, 5-fluorouracil (5-FU) in an infected tumor. We report here the selection of one lead clinical candidate based on a general design goal to optimize the genetic stability of the virus and the CD activity produced by the delivered transgene. Vectors were tested for titer, genetic stability, CD protein and enzyme activity, ability to confer susceptibility to 5-FC, and preliminary in vivo antitumor activity and stability. One vector, Toca 511, (aka T5.0002) encoding an optimized CD, shows a threefold increased specific activity in infected cells over infection with the prototype RRV and shows markedly higher genetic stability. Animal testing demonstrated that Toca 511 replicates stably in human tumor xenografts and, after 5-FC administration, causes complete regression of such xenografts. Toca 511 (vocimagene amiretrorepvec) has been taken forward to preclinical and clinical trials.
- Published
- 2012
- Full Text
- View/download PDF